Stocks and InvestingStocks and Investing
Fri, April 8, 2022
Thu, April 7, 2022
Wed, April 6, 2022
Tue, April 5, 2022

Arlinda Lee Maintained (BNTX) at Strong Buy with Decreased Target to $300 on, Apr 5th, 2022


Published on 2024-10-27 20:18:45 - WOPRAI, Arlinda Lee
  Print publication without navigation


Arlinda Lee of Canaccord Genuity, Maintained "BioNTech SE" (BNTX) at Strong Buy with Decreased Target from $450 to $300 on, Apr 5th, 2022.

Arlinda has made no other calls on BNTX in the last 4 months.



There are 4 other peers that have a rating on BNTX. Out of the 4 peers that are also analyzing BNTX, 3 agree with Arlinda's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Emmanuel Papadakis of "Deutsche Bank" Maintained at Hold and Held Target at $200 on, Friday, April 1st, 2022
  • Simon Baker of "Redburn Partners" Upgraded from Strong Sell to Hold on, Tuesday, February 1st, 2022
  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Decreased Target to $217 on, Tuesday, February 1st, 2022


This is the rating of the analyst that currently disagrees with Arlinda


  • Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $339 on, Wednesday, February 23rd, 2022